Aspire Biopharma (NASDAQ:ASBP) Upgraded by Wall Street Zen to Sell Rating

Wall Street Zen upgraded shares of Aspire Biopharma (NASDAQ:ASBP) to a sell rating in a research report report published on Saturday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aspire Biopharma in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Aspire Biopharma has a consensus rating of “Sell”.

Aspire Biopharma Stock Up 6.5%

Shares of ASBP stock opened at $2.21 on Friday. The firm has a 50 day moving average of $4.07 and a two-hundred day moving average of $11.74. The stock has a market capitalization of $5.94 million, a PE ratio of -4.42 and a beta of 0.81. Aspire Biopharma has a 52 week low of $1.65 and a 52 week high of $632.00.

Aspire Biopharma (NASDAQ:ASBP) last announced its quarterly earnings data on Friday, November 14th. The company reported ($1.60) earnings per share (EPS) for the quarter. The firm had revenue of $0.00 million during the quarter.

Institutional Investors Weigh In On Aspire Biopharma

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Procyon Advisors LLC boosted its stake in Aspire Biopharma by 558.3% in the second quarter. Procyon Advisors LLC now owns 648,411 shares of the company’s stock valued at $174,000 after acquiring an additional 549,911 shares in the last quarter. Crewe Advisors LLC lifted its holdings in shares of Aspire Biopharma by 100.0% in the 2nd quarter. Crewe Advisors LLC now owns 626,854 shares of the company’s stock valued at $169,000 after purchasing an additional 313,427 shares during the last quarter. Optivise Advisory Services LLC boosted its position in shares of Aspire Biopharma by 120.9% in the 2nd quarter. Optivise Advisory Services LLC now owns 235,106 shares of the company’s stock valued at $63,000 after purchasing an additional 128,660 shares during the period. Jane Street Group LLC boosted its position in shares of Aspire Biopharma by 625.8% in the 2nd quarter. Jane Street Group LLC now owns 152,552 shares of the company’s stock valued at $41,000 after purchasing an additional 131,533 shares during the period. Finally, CIBC Bancorp USA Inc. purchased a new position in Aspire Biopharma during the 3rd quarter worth approximately $28,000. 19.17% of the stock is currently owned by institutional investors and hedge funds.

Aspire Biopharma Company Profile

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.